Search results for "Lymph"

showing 10 items of 4590 documents

Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma

2011

Objective  The aim of this study was to evaluate the safety and efficacy profile of pegylated interferon α-2b (PEG-IFN α-2b) in combination with photochemotherapy (PUVA) in the treatment of cutaneous T-cell lymphoma (CTCL) in comparison with standard IFN α plus PUVA. Design  Retrospective cohort study over a period of 7 years. Patients and interventions  A total of 17 consecutive CTCL patients (stage IA–IV) were retrospectively analysed for toxicity and response rates associated with PEG-IFN α-2b (1.5 μg/kg weekly) plus PUVA (n = 9) or standard IFN α-2a (9 MIU 3×/week) plus PUVA (n = 8). Main outcome measures  Differences of response rates (complete/partial remission), progression-free surv…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentCutaneous T-cell lymphomaDermatologymedicine.diseaseDermatologyGastroenterologyDiscontinuationchemistry.chemical_compoundInfectious DiseaseschemistryPegylated interferonInternal medicinePUVA therapyToxicitymedicinebusinessProspective cohort studyAdverse effectPsoralenmedicine.drugJournal of the European Academy of Dermatology and Venereology
researchProduct

Chimioradiothérapie des cancers de l’œsophage : quelles aires ganglionnaires faut-il irradier ?

2014

Esophageal cancer has a high likelihood of distant lymphatic spread even at an early stage. Radiotherapy plays a major role in the management of localized or locally-advanced esophageal cancer with a regional or distant lymph node involvement. Radiotherapy can sterilize micrometastatic nodes and cancer cells in transit in the peri-esophageal fat that are not removed by surgery. After preoperative chemoradiotherapy followed by monobloc esophagectomy including lymph node dissection above and below the diaphragm, the locoregional failure rate was around 3% in the Chemoradiotherapy for Esophageal Cancer followed by Surgery Study Group (CROSS) trial. This is significantly lower than that observe…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentEsophageal cancermedicine.diseaseRadiation therapyDissectionmedicine.anatomical_structureOncologyEsophagectomymedicineDistant Lymph NodeRadiology Nuclear Medicine and imagingRadiologyStage (cooking)businessLymph nodeChemoradiotherapyCancer/Radiothérapie
researchProduct

Relevance of the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) On Non-Relapse Related Mortality (NRM) in Patients with Acute…

2009

Abstract Abstract 3352 Poster Board III-240 Allogeneic HSCT is established as a potent curative therapy in adult patients with high risk ALL. However, due to transplant-related morbidity and lethality the gains in relapse prevention do not necessarily translate into survival advantages in the overall patient population. Defining the role of allogeneic HSCT in ALL patients in first complete remission (CR1) according to leukemia related risk factors, to transplant related risk factors (e.g. HLA matching, conditioning therapy and immunosuppressive treatment), and to comorbidity related risks, remains a major task for upcoming clinical trials. Several retrospective studies suggest that the HCT-…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologyRetrospective cohort studyCell BiologyHematologyHematopoietic stem cell transplantationTotal body irradiationmedicine.diseaseBiochemistryComorbidityFludarabineSurgeryTransplantationhemic and lymphatic diseasesInternal medicinemedicineCumulative incidenceProspective cohort studybusinessmedicine.drugBlood
researchProduct

THU0045 IL-25/IL-17RB AXIS IS ACTIVATED AND ASSOCIATED WITH ILC2 EXPANSION IN GRANULOMATOSIS WITH POLYANGIITIS (GPA)

2019

Background: Pathogenesis of Granulomatosis with polyangiitis (GPA) is still unknown. However, it has been observed a skewing of circulating CD4+ T cells toward the Th17 and Th2 phenotype. The pro-inflammatory cytokine interleukin 25 (IL-25) is a member of IL-17 cytokine family associated to the Th2 immune phenotype. Through the receptor IL17RB, IL-25 further sustains the Th2-type immune response and elicits the expansion of the type 2 innate lymphoid cells (ILC2) and M2 macrophages. A pathogenic role of the innate lymphoid cells in GPA has been recently demonstrated; however, the relevance of IL-25 in this condition remains unexplored. Objectives: Aim of the study was to evaluate the expres…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentInnate lymphoid cellConsensus conferenceGATA3medicine.diseaseGastroenterologyPathogenesisImmune systemCytokineInternal medicineMedicineRituximabbusinessGranulomatosis with polyangiitismedicine.drugPoster Presentations
researchProduct

Significance of Neutrophil to Lymphocyte Ratio (NLR) and Platelet Lymphocyte Ratio (PLR) in Diabetic Foot Ulcer and Potential New Therapeutic Targets

2021

Diabetic foot ulcer (DFU) is a well-known complication of diabetes and a significant burden on the national health systems. The neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio are inexpensive and easily accessible biomarkers that have proved to be useful in several inflammatory, infectious and cardiovascular diseases. We carried out a comprehensive review examining the association of NLR and PLR with the onset and progression of DFU. PLR and NLR were significantly increased in patients with DFU, compared with a control group of T2DM patients without DFU, and correlate well with DFU severity, evaluated by Wagner and IWGDF grading scales. In patients with diabetic foot infect…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentOsteomyelitisGeneral MedicineSystemic inflammationmedicine.diseaseGastroenterologyDiabetic foot ulcerAmputationDiabetes mellitusInternal medicinediabetes diabetic foot ulcer inflammation neutrophil-to-lymphocyte ratio (NLR) platelet lymphocyte ratio (PLR)medicineSurgeryClinical significancemedicine.symptomNeutrophil to lymphocyte ratioComplicationbusiness
researchProduct

Sekundäre Achalasie bei niedrigmalignem Non-Hodgkin-Lymphom und Leiomyomatose der Kardia

2008

A 28-year-old man had been dysphagic for 9 months with a weight loss of 4 kg. A preliminary diagnosis of primary achalasia was made on the basis of typical radiological and manometric findings. Despite balloon dilatation of the cardia the symptoms did not improve and further diagnostic tests were performed. Ultrasound demonstrated a 4 cm tumour below the cardia. But its type and possible malignancy remained uncertain even at laparotomy. But as a malignant tumour was suspected a gastrectomy and omentectomy with removal of the local and regional lymph nodes were performed. After this the symptoms regressed and postoperative food intake was without problem. Histological examination of the surg…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentUltrasoundGeneral Medicinemedicine.diseaseMalignancydigestive system diseasesLymphomaOmentectomyLeiomyomatosisLaparotomymedicineGastrectomyLymphRadiologybusinessDMW - Deutsche Medizinische Wochenschrift
researchProduct

Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C

2021

Mariasanta Napolitano,1 Arne Agerlin Olsen,2 Anne Mette Nøhr,2 Hermann Eichler3 1Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo Reference Regional Center for Thrombosis and Hemostasis, Hematology Unit, Palermo, Italy; 2Novo Nordisk A/S, Biopharm Manufacturing Development, Gentofte, Denmark; 3Saarland University and Saarland University Hospital, Institute of Clinical Haemostaseology and Transfusion Medicine, Homburg (Saar), GermanyCorrespondence: Anne Mette NøhrBiopharm Manufacturing Development, Novo Nordisk A/S, Nybrovej 80, Gentofte 2820, DenmarkTel +45 3075 1619Email amnq@novonordisk.…

medicine.medical_specialtybusiness.industryturoctocog alfa pegolHematologyTuroctocog alfa030204 cardiovascular system & hematologyGastroenterologyJournal of Blood Medicine03 medical and health sciences0302 clinical medicinetemperature stabilityfactor VIII030220 oncology & carcinogenesisAmbient humidityInternal medicinehemic and lymphatic diseasesmedicinePotencyfactor VIII hemophilia A storage flexibility temperature stability turoctocog alfa turoctocog alfa pegolhemophilia Astorage flexibilityturoctocog alfabusinessHot and humidOriginal ResearchJournal of Blood Medicine
researchProduct

Potential Involvement of Impaired Venous Outflow from the Brain in Neurodegeneration: Lessons Learned from the Research on Chronic Cerebrospinal Veno…

2019

About 10 years ago, the so-called chronic cerebrospinal venous insufficiency syndrome was discovered. This clinical entity, which is associated with extracranial venous abnormalities that impair venous outflow from the brain, was initially found exclusively in multiple sclerosis patients. Currently, we know that such venous lesions can also be revealed in other neurological pathologies, including Alzheimer’s and Parkinson’s diseases. Although direct causative role of chronic cerebrospinal venous insufficiency in these neurological diseases still remains elusive, in this paper, we suggest that perhaps an abnormal venous drainage of the brain affects functioning of the glymphatic system, whi…

medicine.medical_specialtychronic cerebrospinal venous insufficiencyDisease030204 cardiovascular system & hematologymultiple sclerosisjugular vein03 medical and health sciences0302 clinical medicineCerebrospinal fluidInternal medicineCranial cavitymedicineballoon angioplastyHumansPharmacologybusiness.industryMultiple sclerosisNeurodegenerationneurodegenerationBrainNeurodegenerative DiseasesGeneral Medicinemedicine.diseaseParkinson diseaseChronic cerebrospinal venous insufficiencymedicine.anatomical_structureVenous InsufficiencyRegional Blood FlowCerebrovascular CirculationChronic DiseaseCardiologyGlymphatic systemAlzheimer's diseaseAlzheimer diseaseJugular Veinsbusiness030217 neurology & neurosurgeryReviews on recent clinical trials
researchProduct

Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice

2018

Bernd Tischer,1 Renato Marino,2 Mariasanta Napolitano3 1Kantar Health, Munich, Germany; 2Haemophilia and Thrombosis Centre, University Hospital of Bari, Apulia, Italy; 3University of Palermo, Reference Regional Center for Thrombosis and Hemostasis Hematology Unit, Palermo, Italy Objectives: To gain insights into the usage of factor VIII (FVIII) products by patients diagnosed with moderate/severe hemophilia A, and to assess the impact and perceived importance of product storage.Methods: In this study, 200 patients diagnosed with moderate or severe hemophilia A across seven countries participated. Data were collected via a 30-minute, face-to-face interview in six countries and via a web-based…

medicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitieshemophilia A recombinant FVIII plasma-derived FVIII storage reconstitution stabilityTreatment Adherence haemophiliaActivities of daily livingMedicine (miscellaneous)030204 cardiovascular system & hematologySevere hemophilia AHaemophiliaHemophilia Astorage03 medical and health sciences0302 clinical medicinePatient satisfactionrecombinant FVIIIplasma-derived FVIIIhemic and lymphatic diseasesMedicine030212 general & internal medicineProduct (category theory)Pharmacology Toxicology and Pharmaceutics (miscellaneous)Original Researchlcsh:R5-920business.industryHealth Policystabilitymedicine.diseasePatient preferenceConjoint analysisProduct choicePatient Preference and AdherenceEmergency medicinereconstitutionbusinesslcsh:Medicine (General)Social Sciences (miscellaneous)Patient Preference and Adherence
researchProduct

Use of wearable cardioverter‐defibrillator in association with catheter ablation for atrial fibrillation‐related tachycardiomyopathy

2019

Implantable cardioverter‐defibrillator (ICD) implantation is not indicated in patients with potentially transient or reversible causes of sudden cardiac death (SCD). Wearable cardioverter‐defibrillator (WCD) is increasingly used for SCD prevention in patients who are temporary at high risk of ventricular arrhythmia. Hereby, we describe a case of tachycardiomyopathy successfully managed with ablation and WCD backup. Implantable cardioverter‐defibrillators are a Class I indication by American College of Cardiology/American Heart Association/Heart Rhythm Society guidelines to prevent SCD in patients with nonischemic dilated cardiomyopathy, New York Heart Association (NYHA) functional class II …

medicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesimplantable cardioverter defibrillatormedicine.medical_treatmentCatheter ablationCase ReportCase Reports030204 cardiovascular system & hematologySudden cardiac death03 medical and health sciences0302 clinical medicineInternal medicinehemic and lymphatic diseasescatheter ablationmedicineatrial fibrillationcardiovascular diseasesEjection fractionwearable cardioverter defibrillatorbusiness.industryDilated cardiomyopathyAtrial fibrillationGeneral Medicinemedicine.diseaseImplantable cardioverter-defibrillator030220 oncology & carcinogenesisHeart failureCardiologycardiovascular systembusinessWearable cardioverter defibrillatorClinical Case Reports
researchProduct